Sanofi — Director's Dealing 2015

Oct 8, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2015-10-06

Reporting Person: Sanofi (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-10-06	Common Stock	P	1107	$449.1383	Acquired	23018099	Indirect
2015-10-06	Common Stock	P	1200	$450.2306	Acquired	23019299	Indirect
2015-10-06	Common Stock	P	1451	$451.3084	Acquired	23020750	Indirect
2015-10-06	Common Stock	P	1768	$452.3727	Acquired	23022518	Indirect
2015-10-06	Common Stock	P	3842	$453.4794	Acquired	23026360	Indirect
2015-10-06	Common Stock	P	4140	$454.4757	Acquired	23030500	Indirect
2015-10-06	Common Stock	P	3601	$455.5580	Acquired	23034101	Indirect
2015-10-06	Common Stock	P	2480	$456.5556	Acquired	23036581	Indirect
2015-10-06	Common Stock	P	2938	$457.6022	Acquired	23039519	Indirect
2015-10-06	Common Stock	P	9730	$458.5797	Acquired	23049249	Indirect
2015-10-06	Common Stock	P	6697	$459.5495	Acquired	23055946	Indirect
2015-10-06	Common Stock	P	12798	$460.7054	Acquired	23068744	Indirect
2015-10-06	Common Stock	P	9271	$461.6131	Acquired	23078015	Indirect
2015-10-06	Common Stock	P	5411	$462.6074	Acquired	23083426	Indirect
2015-10-06	Common Stock	P	5812	$463.7103	Acquired	23089238	Indirect
2015-10-06	Common Stock	P	1190	$464.5745	Acquired	23090428	Indirect
2015-10-06	Common Stock	P	900	$466.0381	Acquired	23091328	Indirect
2015-10-06	Common Stock	P	2200	$467.3464	Acquired	23093528	Indirect
2015-10-06	Common Stock	P	1702	$468.4879	Acquired	23095230	Indirect
2015-10-06	Common Stock	P	2300	$469.4610	Acquired	23097530	Indirect

Footnotes

F1: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").

F3: Purchase prices range from $448.70 to $449.50 per share, inclusive.

F4: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,297,978 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.

F5: Purchase prices range from $449.94 to $450.73 per share, inclusive.

F6: Purchase prices range from $450.99 to $451.94 per share, inclusive.

F7: Purchase prices range from $452.00 to $452.96 per share, inclusive.

F8: Purchase prices range from $453.02 to $454.01 per share, inclusive.

F9: Purchase prices range from $454.03 to $454.92 per share, inclusive.

F10: Purchase prices range from $455.04 to $456.03 per share, inclusive.

F11: Purchase prices range from $456.10 to $457.07 per share, inclusive.

F12: Purchase prices range from $457.10 to $458.03 per share, inclusive.

F13: Purchase prices range from $458.10 to $459.09 per share, inclusive.

F14: Purchase prices range from $459.10 to $460.08 per share, inclusive.

F15: Purchase prices range from $460.13 to $461.12 per share, inclusive.

F16: Purchase prices range from $461.13 to $462.08 per share, inclusive.

F17: Purchase prices range from $462.13 to $463.11 per share, inclusive.

F18: Purchase prices range from $463.15 to $464.10 per share, inclusive.

F19: Purchase prices range from $464.32 to $465.00 per share, inclusive.

F20: Purchase prices range from $465.78 to $466.28 per share, inclusive.

F21: Purchase prices range from $466.89 to $467.79 per share, inclusive.

F22: Purchase prices range from $467.91 to $468.80 per share, inclusive.

F23: Purchase prices range from $468.98 to $469.74 per share, inclusive.